CD24 and cancer: Flow cytometry analysis of FVS− viable dormant tumor cell lines that regrew ex vivo had similar characteristics by the expression of neu antigen, the epithelial cell marker EpCAM, and a predominant CD24+CD44+ fraction over CD24-CD44+ cancer stem cell-like fraction (Fig. 4b–d).